| SABS Past Earnings | ||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|
SAB Biotherapeutics Past Earnings
SABS Past Earnings
— Presenting past earnings and revenue for SAB Biotherapeutics (SABS) from Q1 2022 to Q4 2025, based on our latest update on 5/6/2026. The past earnings numbers are per-share values while the revenue is the grand total for the quarter. Studying these SABS past earnings numbers both in chart format and in tables can help investors visualize any typical seasonality patterns, as well as determine whether the company has grown over time.| SABS Past Revenue | ||||||||||||||||||||||||||||||||||||||||||||||||
|
| SABS Current Stock Quote |
Quotes delayed 20 minutes  Free SABS Email Alerts:
Get Dividend Alerts 
Get SEC Filing Alerts
|
| SABS Stock Price Chart |
| Featured Articles |
| Past Earnings Peers |
| SAB Biotherapeutics (SABS) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:
SAGE Past Earnings SANA Past Earnings SAVA Past Earnings SBTX Past Earnings SCPH Past Earnings SCPS Past Earnings SCTL Past Earnings SCYX Past Earnings SDC Past Earnings SDGR Past Earnings |
SABS Past Earnings Q&A
What was the best and worst SABS past earnings results?
For SAB Biotherapeutics, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?
For SAB Biotherapeutics, I'm wondering what the company's very best and worst earnings results have been, on an earnings per share basis?
✔️Accepted answer:
The highest SABS past earnings result in our data set was 0.200/share posted in Q1 2022, while the lowest was in Q4 2023 when SABS posted -3.840/share.
Suggested answer:
The biggest top line earnings performance — aka revenue — quarter was in Q1 2022 when SABS reported 0.01B in revenue, while the quarter with the lowest revenue in our data set was Q4 2025 at NA of revenue.
Suggested answer:
There are 15 SABS past earnings results in our data set.
On this page we presented the SABS past earnings date information for SAB Biotherapeutics. Reviewing that
SABS Past Earnings for the company, we see that the highest past earnings result in our data set was in Q1 2022, when SABS posted earnings of 0.200/share. Meanwhile the lowest SABS past earnings result was in Q4 2023, when SABS posted earnings of -3.840/share. Turning to top line revenue performance, the biggest revenue quarter in our data set was seen in Q1 2022 when SABS reported 0.01B in revenue, while the smallest revenue quarter was Q4 2025 when SABS reported NA in revenue.
Any self directed investor doing their due diligence on SABS or any other given stock can benefit from researching all of the SAB Biotherapeutics past earnings — and here, we present each quarter's result all together on one page for easy comparison. Studying this information can help when projecting future earnings, as well as determining whether the past earnings trajectory justifies the current stock value. That's why we bring you PastEarnings.com to make it easy for investors to investigate SAB Biotherapeutics past earnings, or the past earnings information for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for earnings surprises history (beat/miss data) as well as next earnings dates for SABS. Thanks for visiting, and the next time you need to research SABS past earnings or those of another stock, we hope you'll think of our site, as your go-to past earnings research resource of choice.
Also recommended: SRPT Split History, COR 13F Filers, TECL Dividend History.
SABS Past Earnings | www.PastEarnings.com | Copyright © 2020 - 2026, All Rights Reserved
Nothing in PastEarnings.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Use and
Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at
least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.